A review of 34 European studies has found broad evidence that obesity is associated with lower employment, more sickness absence and impaired work performance. Separate OECD modelling estimates that overweight and related conditions may leave average GDP across its member countries 3.3% lower over the period from 2020 to 2050 than it would otherwise have been. However, both findings describe population-level patterns. They do not show that a person’s body size is a reliable measure of how well that individual will perform at work.
The systematic review, published in Obesity Reviews in June 2026, brought together European research published from 2014 onwards.
Twenty of the 34 studies found evidence of lower employment among people living with obesity compared with people in the overweight or healthy BMI categories. Seven studies associated obesity with greater sickness absence, while seven reported impaired work performance.
The pattern is strong enough to make workforce health a business issue. It is not strong enough to prove that obesity alone caused each outcome. Health conditions, job demands, income, education, discrimination and other factors may all contribute.
The paper’s funding disclosure states that Novo Nordisk supported the literature review, analysis and medical writing. That does not invalidate the findings, but it is relevant context when assessing the conclusions.
Absence is only part of the cost
Absenteeism is relatively easy to measure. It is the time an employee is away from work because of illness.
Presenteeism is less visible. It occurs when someone is at work but a health problem limits concentration, pace, mobility or another part of their performance.
In its 2019 economic modelling, the OECD examined overweight across 52 countries. The report used overweight to mean a body mass index above 25, so its figures include both overweight and obesity.
For the period from 2020 to 2050, the OECD estimated an average annual reduction in the workforce equivalent to 54 million full-time workers. Reduced employment accounted for 28 million of that total, presenteeism for 18 million and absenteeism for 8 million.
This does not mean 54 million identifiable people will lose their jobs each year. It is a modelled full-time-equivalent figure that converts changes in employment and productivity into a common unit.
The OECD estimated that presenteeism accounted for nearly half of the labour-market output lost because of overweight. That means a company looking only at sick-leave totals may miss a large part of the cost.
The 3.3% GDP figure needs context
The OECD’s 3.3% estimate is sometimes described simply as the economic cost of obesity. That is too narrow.
The model covers overweight, including obesity, and combines three effects: shorter life expectancy, higher healthcare spending and lower labour-market output. It is a comparison with a modelled counterfactual, not a measured annual bill for employers. Nor does it show that obesity alone causes GDP to be 3.3% lower.
Even so, scale matters. The World Health Organization estimates that one in eight people worldwide were living with obesity in 2022. When a condition affects such a large share of the population, even modest average effects can influence healthcare spending, labour participation and productivity.
WHO classifies obesity as a chronic, relapsing disease arising from interactions between genetics, neurobiology, eating behaviour, access to healthy food, market forces and the wider environment. Treating it simply as a failure of willpower ignores much of the evidence. It also overstates how much control an employer has over the causes.
Weight is a poor measure of individual performance
Population averages cannot determine how a particular employee will perform. A person living with obesity may have no work limitations. Another person with a BMI in the healthy range may have a chronic condition that affects attendance or productivity.
BMI itself is a screening measure rather than a complete assessment of individual health. The US Centers for Disease Control and Prevention says it does not directly measure body fat and cannot distinguish between fat, muscle and bone mass. For an individual, it should be considered alongside other clinical information.
Weight discrimination may also influence the employment patterns found in research. A 2020 international consensus statement concluded that weight stigma is widespread and causes social and economic harm. Bias in recruitment, promotion, pay or everyday treatment can damage employment outcomes independently of a person’s health.
For employers, the boundary should be clear. They can measure attendance, safety, output and job performance directly. Body size is a poor substitute for any of them.
There may also be legal duties. Protections vary between countries. In the United States, the Americans with Disabilities Act may apply when obesity or a related condition meets the legal definition of disability. Covered employers may then be required to provide a reasonable accommodation. Obesity is not automatically treated as a disability in every case, so local law and the employee’s circumstances matter.
Wellness programmes are not guaranteed to pay for themselves
Employers can influence part of the environment in which people spend their working day. That does not mean every workplace wellness programme will improve health or reduce costs.
The OECD model includes workplace wellness and efforts to reduce sedentary behaviour among the policies that may produce economic gains. However, those results come from modelling and depend on assumptions about implementation, participation and lasting behaviour change.
A large randomised clinical trial published in JAMA offers a useful counterpoint. The trial involved 32,974 employees at a large US warehouse retailer. It tested a broad workplace wellness programme rather than an obesity treatment programme.
After 18 months, the share of employees reporting regular exercise was 8.3 percentage points higher at worksites offered the programme. The share reporting that they were actively managing their weight was 13.6 percentage points higher.
However, researchers found no significant differences in clinical health measures, healthcare spending or use, absenteeism, employee tenure or job performance.
The trial does not prove that workplace programmes never work. It shows that changes in reported behaviour do not automatically produce measurable savings or productivity gains within 18 months.
A more defensible approach is to address conditions that affect work directly. This may include suitable equipment for different body sizes, opportunities to move during the day, flexible access to medical care, confidential health support and reasonable accommodations for employees who need them.
Programmes should protect privacy and avoid making weight loss the only measure of success. Employers can instead track outcomes such as absence, retention, safety and employee-reported ability to work.
Obesity medicines have changed the benefits calculation
GLP-1 medicines have added a new question for employers, particularly in the United States, where many companies help finance employee health insurance.
These medicines include liraglutide, semaglutide and tirzepatide. In December 2025, WHO issued its first guideline on GLP-1 therapies for obesity. It conditionally recommended that they may be used for the long-term treatment of adults with obesity, excluding pregnant women, as part of comprehensive care.
The recommendation was conditional because questions remain about long-term use, what happens when treatment stops, cost, health-system capacity and fair access.
For employers, demand is already affecting budgets. KFF research based on its 2025 Employer Health Benefits Survey found that 43% of US firms with at least 5,000 workers covered GLP-1 medicines for weight loss in their largest health plan, up from 28% in 2024.
Among employers of that size offering coverage, 59% said use was higher than expected. Two-thirds, or 66%, said the medicines had a significant effect on prescription drug spending.
The possible return remains uncertain. Better health may reduce future medical costs and absence, but treatment may continue for years. Employees also change jobs, which means the company paying for treatment today may not receive all the financial benefit later.
The practical response is to measure work directly
The evidence supports a limited but useful conclusion. Poor workforce health can reduce employment and productivity, and obesity forms part of that picture. The evidence does not support judging workers by appearance or using weight targets as a substitute for performance management.
Employers have clearer levers. They can design jobs and equipment around the people who use them, make medical care easier to access, manage absence constructively, provide reasonable accommodations and assess employees against the actual requirements of their work.
The unresolved question is which interventions improve health enough to justify their cost. GLP-1 medicines may change the answer for some employers and employees, but evidence on their long-term financial return is still developing.
Until that becomes clearer, businesses should measure the outcomes they care about directly. They do not need body weight as a proxy.
